Your browser doesn't support javascript.
loading
Staging Parkinson's Disease According to the MNCD (Motor/Non-motor/Cognition/Dependency) Classification Correlates with Disease Severity and Quality of Life.
Santos-García, Diego; de Deus Fonticoba, Teresa; Cores Bartolomé, Carlos; Feal Painceiras, Maria J; Íñiguez-Alvarado, Maria Cristina; García Díaz, Iago; Jesús, Silvia; Buongiorno, Maria Teresa; Planellas, Lluís; Cosgaya, Marina; García Caldentey, Juan; Caballol, Nuria; Legarda, Ines; Hernández Vara, Jorge; Cabo, Iria; López Manzanares, Lydia; González Aramburu, Isabel; Ávila Rivera, Maria A; Gómez Mayordomo, Víctor; Nogueira, Víctor; Puente, Víctor; Dotor García-Soto, Julio; Borrué, Carmen; Solano Vila, Berta; Álvarez Sauco, María; Vela, Lydia; Escalante, Sonia; Cubo, Esther; Carrillo Padilla, Francisco; Martínez Castrillo, Juan C; Sánchez Alonso, Pilar; Alonso Losada, Maria G; López Ariztegui, Nuria; Gastón, Itziar; Kulisevsky, Jaime; Menéndez González, Manuel; Seijo, Manuel; Ruiz Martínez, Javier; Valero, Caridad; Kurtis, Mónica; González Ardura, Jessica; Alonso Redondo, Ruben; Ordás, Carlos; López Díaz, Luis M; McAfee, Darrian; Calopa, Matilde; Carrillo, Fátima; Escamilla Sevilla, Francisco; Freire-Alvarez, Eric; Gómez Esteban, Juan Carlos.
Afiliación
  • Santos-García D; CHUAC, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain.
  • de Deus Fonticoba T; CHUF, Complejo Hospitalario Universitario de Ferrol, A Coruña, Spain.
  • Cores Bartolomé C; CHUAC, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain.
  • Feal Painceiras MJ; CHUAC, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain.
  • Íñiguez-Alvarado MC; CHUAC, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain.
  • García Díaz I; CHUAC, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain.
  • Jesús S; Unidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain.
  • Buongiorno MT; CIBERNED (Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas), Madrid, Spain.
  • Planellas L; Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain.
  • Cosgaya M; Clínica del Pilar, Barcelona, Spain.
  • García Caldentey J; Hospital Clínic de Barcelona, Barcelona, Spain.
  • Caballol N; Centro Neurológico Oms 42, Palma de Mallorca, Spain.
  • Legarda I; Consorci Sanitari Integral, Hospital Moisés Broggi, Sant Joan Despí, Barcelona, Spain.
  • Hernández Vara J; Hospital Universitario Son Espases, Palma de Mallorca, Spain.
  • Cabo I; CIBERNED (Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas), Madrid, Spain.
  • López Manzanares L; Hospital Universitario Valld' Hebron, Barcelona, Spain.
  • González Aramburu I; Complejo Hospitalario Universitario de Pontevedra (CHOP), Pontevedra, Spain.
  • Ávila Rivera MA; Hospital Universitario La Princesa, Madrid, Spain, Pontevedra, Spain.
  • Gómez Mayordomo V; CIBERNED (Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas), Madrid, Spain.
  • Nogueira V; Hospital Universitario Marqués de Valdecilla, Santander Spain.
  • Puente V; Consorci Sanitari Integral, Hospital General de LΉospitalet, LΉospitalet de Llobregat, Barcelona,Spain.
  • Dotor García-Soto J; Hospital Universitario Cí Anico San Carlos, Madrid, Spain.
  • Borrué C; Hospital Da Costa, Burela, Lugo,Spain.
  • Solano Vila B; Hospital del Mar, Barcelona, Spain.
  • Álvarez Sauco M; Hospital Universitario Virgen Macarena, Sevilla, Spain.
  • Vela L; Hospital Infanta Sofía, Madrid, Spain.
  • Escalante S; Institut d'Assistència Sanitària (IAS) - Institut Cataè de la Salut, Girona, Spain.
  • Cubo E; Hospital General Universitario de Elche, Elche, Spain.
  • Carrillo Padilla F; Fundación Hospital de Alcorcón, Madrid,Spain.
  • Martínez Castrillo JC; Hospital de Tortosa Verge de la Cinta (HTVC), Tortosa, Tarragona, Spain.
  • Sánchez Alonso P; Complejo Asistencial Universitario de Burgos, Burgos, Spain.
  • Alonso Losada MG; Hospital Universitario de Canarias, San Cristóbal de la Laguna, Santa Cruz de Tenerife, Spain.
  • López Ariztegui N; Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain.
  • Gastón I; Hospital Universitario Puerta de Hierro, Madrid, Spain.
  • Kulisevsky J; Hospital Ávaro Cunqueiro, Complejo Hospitalario Universitario de Vigo (CHUVI), Vigo, Spain.
  • Menéndez González M; Complejo Hospitalario de Toledo, Toledo, Spain.
  • Seijo M; Complejo Hospitalario de Navarra, Pamplona, Spain.
  • Ruiz Martínez J; CIBERNED (Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas), Madrid, Spain.
  • Valero C; Hospital de Sant Pau, Barcelona,Spain.
  • Kurtis M; Hospital Universitario Central de Asturias, Oviedo,Spain.
  • González Ardura J; Complejo Hospitalario Universitario de Pontevedra (CHOP), Pontevedra, Spain.
  • Alonso Redondo R; Hospital Universitario Donostia, San Sebastián, Spain.
  • Ordás C; Hospital Arnau de Vilanova, Valencia, Spain.
  • López Díaz LM; Hospital Ruber Internacional, Madrid, Spain.
  • McAfee D; Hospital de Cabueñes, Gijón, Spain.
  • Calopa M; Hospital Universitario Lucus Augusti (HULA), Lugo,Spain.
  • Carrillo F; Hospital Rey Juan Carlos, Madrid, Spain, Madrid, Spain.
  • Escamilla Sevilla F; Hospital Ávaro Cunqueiro, Complejo Hospitalario Universitario de Vigo (CHUVI), Vigo, Spain.
  • Freire-Alvarez E; University of Maryland School of Medicine, College Park, MD, USA.
  • Gómez Esteban JC; Unidad de Trastornos del Movimiento, Servicio de Neurología, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
J Parkinsons Dis ; 13(3): 379-402, 2023.
Article en En | MEDLINE | ID: mdl-36911948
ABSTRACT

BACKGROUND:

Recently, a novel simple classification called MNCD, based on 4 axes (Motor; Non-motor; Cognition; Dependency) and 5 stages, has been proposed to classify Parkinson's disease (PD).

OBJECTIVE:

Our aim was to apply the MNCD classification in a cohort of PD patients for the first time and also to analyze the correlation with quality of life (QoL) and disease severity.

METHODS:

Data from the baseline visit of PD patients recruited from 35 centers in Spain from the COPPADIS cohort fromJanuary 2016 to November 2017 were used to apply the MNCD classification. Three instruments were used to assess QoL1) the 39-item Parkinson's disease Questionnaire [PDQ-39]); PQ-10; the EUROHIS-QOL 8-item index (EUROHIS-QOL8).

RESULTS:

Four hundred and thirty-nine PD patients (62.05±7.84 years old; 59% males) were included. MNCD stage wasstage 1, 8.4% (N = 37); stage 2, 62% (N = 272); stage 3, 28.2% (N = 124); stage 4-5, 1.4% (N = 6). A more advancedMNCD stage was associated with a higher score on the PDQ39SI (p < 0.0001) and a lower score on the PQ-10 (p< 0.0001) and EUROHIS-QOL8 (p< 0.0001). In many other aspects of the disease, such as disease duration, levodopa equivalent daily dose, motor symptoms, non-motor symptoms, and autonomy for activities of daily living, an association between the stage and severity was observed, with data indicating a progressive worsening related to disease progression throughout the proposed stages.

CONCLUSION:

Staging PD according to the MNCD classification correlated with QoL and disease severity. The MNCD could be a proper tool to monitor the progression of PD.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad de Parkinson Tipo de estudio: Diagnostic_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad de Parkinson Tipo de estudio: Diagnostic_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2023 Tipo del documento: Article